2月2日，新诺威跌7.59%，成交额7.02亿元。两融数据显示，当日新诺威获融资买入额5385.57万元，融 资偿还6030.31万元，融资净买入-644.75万元。截至2月2日，新诺威融资融券余额合计4.66亿元。 机构持仓方面，截止2025年9月30日，新诺威十大流通股东中，香港中央结算有限公司位居第二大流通 股东，持股1778.22万股，相比上期减少321.69万股。中欧医疗健康混合A（003095）位居第三大流通股 东，持股1632.25万股，相比上期减少386.14万股。工银前沿医疗股票A（001717）位居第四大流通股 东，持股1400.01万股，相比上期增加200.01万股。汇添富创新医药混合A（006113）位居第五大流通股 东，持股1227.70万股，相比上期增加248.44万股。易方达创业板ETF（159915）位居第九大流通股东， 持股786.80万股，相比上期减少132.53万股。中银创新医疗混合A（007718）位居第十大流通股东，持 股639.69万股，为新进股东。中欧医疗创新股票A（006228）退出十大流通股东之列。 融资方面，新诺威当日融资买入5385.57万元。当前融资余额 ...

每经记者|章光日 每经编辑|何小桃 吴永久 1月30日早上，新诺威（SZ300765，市值546亿元）迎来新任总经理和新任董事会秘书，二人皆为"90后"。不过，资本市场对此反应并不友好，新诺威早 盘股价最大跌幅一度达到18%。而不久前，新诺威还发布了2025年年度业绩预亏公告，净利润较2024年同期下降416%至575%。 新任总经理和董秘皆为"90后" 1月30日，新诺威发布关于变更公司总经理、董事会秘书及证券事务代表的公告。该公告显示，姚兵申请辞去公司总经理职务，戴龙申请辞去公司董事会 秘书及证券事务代表职务，与此同时，公司董事会同意聘任戴龙担任公司总经理，同意聘任徐雯担任公司董事会秘书及证券事务代表。 而新诺威新任总经理戴龙和新任董事会秘书皆为"90后"。 戴龙1992年6月出生，本科学历，2016年12月加入新诺威，历任公司财务经理、证券事务代表、董事会秘书。目前，戴龙还担任新诺威的董事和财务总 监。新诺威2024年年报显示，尽管身兼数职，但戴龙2024年从公司获得的税前报酬总额仅为22.32万元。 徐雯1990年4月出生，硕士学历，从2024年5月开始担任新诺威的董事。不过，新诺威2024年年报显示 ...

Group 1 - New CEO and Secretary appointed at XinNuoWei, both born in the 1990s, leading to a negative market reaction with a stock price drop of up to 18% [1][10] - The company announced a significant expected net profit loss for 2025, projecting a decline of 416% to 575% compared to 2024 [1][12] - The new CEO, Dai Long, has been with the company since 2016 and previously held multiple roles, while the new Secretary, Xu Wen, has a master's degree and will also serve as a board member [2][7] Group 2 - XinNuoWei's main business focuses on biopharmaceuticals and functional foods, with recent developments in ADC, mRNA vaccines, and antibody drugs [12] - The projected net profit for 2025 is expected to be between -1.7 billion to -2.55 billion, marking a significant decline from a profit of 537.26 million in 2024 [12][13] - The decline in performance is attributed to increased R&D expenses, the acquisition of a controlling stake in a subsidiary, and reduced profit margins in the functional raw materials segment [14]

Core Viewpoint - Newnow (300765) has appointed a new general manager and board secretary, both born in the 1990s, but the market reacted negatively, with the stock price dropping by up to 18% in early trading. The company also announced a significant expected net profit decline for 2025, with a decrease of 416% to 575% compared to the same period in 2024 [1]. Group 1 - The new general manager, Dai Long, born in June 1992, has a bachelor's degree and joined Newnow in December 2016, holding multiple roles including financial manager, securities affairs representative, and board secretary [1]. - Despite holding several positions, Dai Long's pre-tax compensation for 2024 was only 223,200 yuan [1]. - Newnow's main business focuses on the research, production, and sales of biopharmaceuticals and functional foods and raw materials, with a focus on cutting-edge areas such as ADC, mRNA vaccines, and antibody drugs [1].

1月23日，新诺威涨5.02%，截至发稿，报39.77元/股，成交3.50亿元，换手率0.65%，总市值558.61亿 元。 截至发稿，成曦累计任职时间9年264天，现任基金资产总规模2369.54亿元，任职期间最佳基金回报 131.04%， 任职期间最差基金回报-67.89%。 刘树荣累计任职时间8年192天，现任基金资产总规模1276.84亿元，任职期间最佳基金回报194.12%， 任职期间最差基金回报-48.01%。 资料显示，石药创新制药股份有限公司位于河北省石家庄市栾城区张举路62号,香港湾仔港湾道18号中 环广场32楼3206室，成立日期2006年4月5日，上市日期2019年3月22日，公司主营业务涉及功能食品的 研发、生产与销售。主营业务收入构成为：功能食品及原料88.93%，生物制药8.91%，其他2.16%。 从新诺威十大流通股东角度 数据显示，易方达基金旗下1只基金位居新诺威十大流通股东。易方达创业板ETF（159915）三季度减 持132.53万股，持有股数786.8万股，占流通股的比例为0.63%。根据测算，今日浮盈赚取约1494.92万 元。 易方达创业板ETF（159915）成立日 ...

Group 1 - The health industry is becoming a core pillar for high-quality economic and social development, with functional foods and skincare products being key sectors to meet public demand for a better life and establish a comprehensive health service system [1] - The Beijing University Life Sciences East China Industry Research Institute's Functional Food/Skin Care Engineering Technology Center will hold its inauguration ceremony on January 18, 2026, in Qidong, Jiangsu [1] - The center aims to promote the development of the life sciences industry, facilitate the transformation of scientific achievements, and provide public technical services as a new high-end platform [3] Group 2 - The center has made significant technological achievements in plant synthetic biology and natural product innovation, particularly in the transformation and industrialization of rare ginsenosides from ginseng and Panax notoginseng, achieving world-leading levels [3] - The center will continue to promote the application of its projects in functional foods and skincare products, addressing the slow metabolism and absorption issues of traditional ginseng saponins [3] - With the global aging population and increasing attention to public health, the functional food and skincare market is expected to experience significant growth, with a focus on natural products as essential components [10]

数据显示，金元顺安基金旗下1只基金重仓新诺威。金元顺安医疗健康混合A类（007861）三季度增持 1.31万股，持有股数4.88万股，占基金净值比例为3.75%，位居第十大重仓股。根据测算，今日浮亏损 失约10.74万元。 金元顺安医疗健康混合A类（007861）成立日期2021年7月29日，最新规模3836.83万。今年以来收益 7.33%，同类排名1797/8840；近一年收益14.79%，同类排名5884/8094；成立以来亏损53.75%。 金元顺安医疗健康混合A类（007861）基金经理为陈铭杰、张海东。 截至发稿，陈铭杰累计任职时间2年82天，现任基金资产总规模7269.52万元，任职期间最佳基金回报 8.68%， 任职期间最差基金回报-24.12%。 张海东累计任职时间144天，现任基金资产总规模6.28亿元，任职期间最佳基金回报5.45%， 任职期间 最差基金回报-1.14%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 1月15日 ...

Group 1 - The core point of the news is that New Nuo Wei's stock price decreased by 1.22%, reaching 36.51 yuan per share, with a total market capitalization of 51.282 billion yuan [1] - New Nuo Wei is primarily engaged in the research, production, and sales of functional foods, with 88.93% of its revenue coming from functional foods and raw materials, 8.91% from biopharmaceuticals, and 2.16% from other sources [1] Group 2 - According to data, Pengyang Fund has a significant holding in New Nuo Wei, with its Pengyang Medical Health Mixed A Fund increasing its holdings by 123,500 shares to a total of 181,200 shares, representing 5.68% of the fund's net value [2] - The Pengyang Medical Health Mixed A Fund has achieved a year-to-date return of 27.83% and a one-year return of 26.14%, ranking 3388 out of 8087 and 3373 out of 8085 respectively [2] - The fund manager, Zhu Guoqing, has a tenure of 18 years and 289 days, with a total fund asset size of 862 million yuan, while the co-manager, Cui Jieming, has a tenure of 2 years and 62 days, managing assets of 147 million yuan [2]

Group 1 - The core point of the article highlights the recent decline in the stock price of New Nuo Wei, which fell by 5.36% to 37.44 CNY per share, with a trading volume of 245 million CNY and a turnover rate of 0.46%, resulting in a total market capitalization of 52.588 billion CNY [1] - New Nuo Wei, officially known as Shiyao Innovation Pharmaceutical Co., Ltd., is based in Shijiazhuang, Hebei Province, and was established on April 5, 2006. The company went public on March 22, 2019, and its main business involves the research, development, production, and sales of functional foods [1] - The revenue composition of New Nuo Wei is primarily from functional foods and raw materials at 88.93%, followed by biopharmaceuticals at 8.91%, and other sources at 2.16% [1] Group 2 - From the perspective of major fund holdings, data indicates that a fund under Jianxin Fund has a significant position in New Nuo Wei. Jianxin Medical Health Industry Stock A (008923) increased its holdings by 590,300 shares in the third quarter, bringing the total to 1.4473 million shares, which constitutes 4.74% of the fund's net value, ranking it as the seventh-largest holding [2] - Jianxin Medical Health Industry Stock A (008923) was established on December 28, 2021, with a current scale of 702 million CNY. Year-to-date returns are at 41.64%, ranking 1006 out of 4197 in its category; over the past year, returns are 40.12%, ranking 959 out of 4179; and since inception, returns are 39.64% [2]

三主粮（南京）生命科学技术有限公司是一家集研发、服务、教育、销售于一体的应用研究型企业。公 司秉持"科技领先、专业支撑、益业合作、贴心服务"原则，长期专注食药同源功能食品的深度开发，围 绕专用型营养食品与立体营养健康管理体系，为慢性病及亚健康人群提供以改善体检指标为目标的健康 养愈服务，致力于打造"15分钟健康养愈服务圈"。 晨报讯（通讯员 石珂 高金军 南京晨报/爱南京记者 卢斌）近日，江苏省知识产权局公布2025年度第四 批企业知识产权管理贯标备案单位名单，江北新区共有16家企业成功入选，南京国家农创中心入驻企业 ——三主粮（南京）生命科学技术有限公司凭借在知识产权创造、运用与管理领域的规范体系建设，位 列其中。 "贯标"即企业贯彻实施《企业知识产权管理规范》国家标准。该项备案旨在引导企业建立科学、规范、 系统的知识产权管理体系，全面提升核心竞争力。通过备案的单位，意味着其知识产权管理工作获得省 级层面认可，在项目申报、政策扶持等方面将具备更显著优势。 （来源：南京晨报） 转自：南京晨报 三主粮（南京）生命科学技术有限公司重点关注银发人群与妊娠期糖尿病人群等特定健康需求领域。针 对银发人群的机能特点与营养 ...